First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA
4 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Read more
*Estimates of patients treated reflect global data since launch (Apr 2014-Mar 2023; US=59% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.
When managing plaque psoriasis,
your patients may be quietly struggling on topicals
While topicals may be efficacious for some,
of patients on topical therapy find it to be burdensome to apply 1,*,†
In patients with limited skin involvement using topicals:
48% of patients had no BSA reduction after a mean duration of 6.9 months of topical therapy 2,‡
FOR PATIENTS WITH PLAQUE PsO IN SPECIAL AREAS, TOPICALS MAY NOT BE MEETING THEIR TREATMENT NEEDS 2,3
of patients with scalp psoriasis currently using topical therapy have experienced persistent scalp symptoms 2,‡,§
“It used to take me washing my hair 2 to 3 times to get all the oil out, and then I would still have some residue left weighing down my hair.”
—Genine, an actual patient compensated for her time
*Based on the UPLIFT survey, a multinational online survey conducted from March 2 to June 3, 2020, including adult patients (≥18 years of age) who reported that they had been diagnosed with plaque psoriasis and/or psoriatic arthritis by a healthcare professional. 3806 patients were surveyed in the United States, Canada, United Kingdom, France, Germany, Italy, Spain, and Japan. †Among n=3129 patients with PsO and/or PsA who had current or prior topical treatment. ‡Based on a real-world study of 304 adult systemic-naïve patients with mild to moderate (BSA ≤10%) plaque psoriasis from a survey of physicians. Data were drawn from the 2017 to 2018 Adelphi Psoriasis Disease Specific Programme. Most patients were receiving a generic topical steroid formulation at the time of consultation (72.7%, n=221); 23.4% (n=71) were receiving a generic topical non-steroid formulation, and 24.7% (n=75) were receiving advanced/branded topical products with multiple active formulations. §Of those previously affected with scalp psoriasis, 76% (n=120/158) still had residual symptoms on their scalp.
BSA, body surface area; PsA, psoriatic arthritis; PsO, plaque psoriasis.
Patients who are struggling with topical therapy may be ready for systemic treatment 4,5
Contraindications
Otezla® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulationWarnings and Precautions
Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapyContraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Otezla is indicated for the treatment of:
Please click here for the full Prescribing Information.
References: 1. Lebwohl M, Langley RG, Paul C, et al. Dermatol Ther (Heidelb). 2022;12(1):61-78. 2. Kaplan D, Hetherington J, Lucas J, et al. J Dermatolog Treat. 2022;33(6):2844-2852. 3. Papp K, Reich K, Leonardi CL, et al. J Am Acad Dermatol. 2015;73(1):37-49. 4. Strober B, Ryan C, van de Kerkhof P, et al; International Psoriasis Council Board Members and Councilors. J Am Acad Dermatol. 2020;82(1):117-122. 5. Bhutani T, Haberman R, Khattri S, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide. psoriasis.org/the-pocket-guide/.